Founded in 2009 and home for approximately 1000 employees, Easton Biopharmaceuticals (registered capital of CNY 90millon) is a high-tech pharmaceutical company with focus on research, development, manufacture and commercialization of Pharmaceutical products. As a capable pharmaceutical company, we own various types of GMP-compliant manufacturing facilities. Our products ranging from API to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution.
Easton owns five wholly funded subsidiaries:
Sichuan Sunheal Pharmaceutical Co., Ltd.
Sichuan Qingmu Pharmaceutical Co., Ltd.
Tibetan Runhe Pharmaceutical Co., Ltd.
Chengdu Shuode Pharmaceutical Co., Ltd.
Chengdu Unovel Pharmaceutical Co., Ltd.
Among which, Sichuan Qingmu Pharmaceutical co., ltd. is mainly engaged in the manufacture and sales of API and pharmaceutical intermediates; Sichuan Sunheal Pharmaceutical Co., Ltd. and Tibetan Runhe Pharmaceutical Co., Ltd. are mainly engaged in the promotion and distribution of FDFs; Chengdu Shuode Pharmaceutical Co., Ltd. is located in Chengdu Tianfu International Biological City, which is under construction and Chengdu Unovel Pharmaceutical Co., Ltd. is committed to research and development of biological drugs.
We own an efficient and vigorous team of professionals. All Research and development centers are led by experts with Ph.D. degree. We are equipped with a provincial enterprise technology center and post-doctoral workstation which was supported by talents and scientists from the “national people plan" and the provincial "thousand-person plan", which as a team is identified as the top innovation team in Sichuan Province by provincial government. Moreover, our leaders of production & quality system have always being demonstrating their superior knowledge and extensive experience in both GMP expertise and EU/US GMP authentication.
In order to ensure that the company's strategy is thoroughly and effectively implemented, we have designed and applied an effective control framework, covering the four major segments of the strategy making, scheme planning and budgeting, employee incentives and management reporting.
Adhering to our target of “Self-fulfillment, serving for all, becoming the most valued and trusted pharmaceutical company for our customers around the world”, Easton will be committed to be a patient oriented, clinic-needs guided company. We aim to develop and produce novel and generic drugs in the main areas of Diabetics, Cardiovascular, Oncology, Anesthetic, Analgesics and pediatric therapeutic categories.
The pharmaceutical market in China is changing rapidly, but the new business opportunities are greater than ever. Based on our profound understanding of this market, we will turn these opportunities into success. We would be the ideal partner for international pharmaceutical companies entering in Chinese market.